15% body weight reduction in clinical trials. Here's what the headlines skip.
Semaglutide mimics GLP-1, the hormone your gut releases when you eat. It tells your pancreas to release more insulin, slows gastric emptying so you feel full longer, and signals your hypothalamus to reduce appetite. The weight loss is real and substantial — but it's a signal override, not a metabolic repair. Stop taking it and your original hunger signaling returns. That's not an argument against using it. It's an argument for pairing it with compounds that address the underlying metabolic dysfunction — AOD-9604 for targeted lipolysis, Ipamorelin + CJC-1295 for lean mass preservation during the weight-loss phase. Use the override. Fix the foundation.
Semaglutide
Semaglutide (GLP-1 Receptor Agonist)
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has shown significant weight loss effects in clinical trials. It works by mimicking the natural GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, and reducing appetite via central nervous system pathways.
Technical details
- CAS number
- 910463-68-2
- Molecular formula
- C187H291N45O59
MECHANISM OF ACTION
Semaglutide binds to and activates GLP-1 receptors, which are expressed in pancreatic beta cells, the gastrointestinal tract, and appetite-regulating centers in the hypothalamus. This triple mechanism — increased glucose-dependent insulin secretion, delayed gastric emptying, and reduced appetite signaling — produces substantial and sustained weight loss. Unlike earlier GLP-1 agonists, Semaglutide has an extended half-life (~1 week) allowing once-weekly dosing.
RESEARCH HIGHLIGHTS
Semaglutide 2.4mg once weekly produced 14.9% mean body weight reduction vs 2.4% placebo at 68 weeks (STEP-1 Trial)
Semaglutide reduces major adverse cardiovascular events by 20% in overweight/obese patients with established CVD (SELECT Trial)
GLP-1 receptor agonists show neuroprotective effects and reduced neuroinflammation in preclinical models
RESEARCH PROTOCOLS
For laboratory use only. Not medical advice.
Start with 0.25mg for 4 weeks to assess GI tolerance. Do NOT start at therapeutic dose.
Titrate: 0.25mg → 0.5mg → 1.0mg over 8 weeks. Expected weight loss: 10-15% body weight at 16 weeks.
Full STEP-1 trial dose. Requires careful GI side effect management. Nausea most common in first 4 weeks.
PAIRS WELL WITH
ORDER
SAFETY & CONTRAINDICATIONS
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy or breastfeeding
- Severe gastrointestinal disease (gastroparesis)
Most common: nausea (up to 44% initially, typically resolves within 4 weeks), vomiting, diarrhea, constipation, abdominal pain. Less common: gallbladder/biliary disease, increased heart rate (2-3 BPM mean increase), hypoglycemia (when combined with sulfonylureas or insulin). Rare: acute pancreatitis, medullary thyroid tumors (animal models only).
For research and laboratory use only. Not intended for human consumption. Not for diagnostic or therapeutic purposes.